The Onset of In-Vivo Dehydration in Gas -Based Intraperitoneal Hyperthermia and Its Cytotoxic Effects on Colon Cancer Cells
- PMID: 35847916
- PMCID: PMC9278806
- DOI: 10.3389/fonc.2022.927714
The Onset of In-Vivo Dehydration in Gas -Based Intraperitoneal Hyperthermia and Its Cytotoxic Effects on Colon Cancer Cells
Abstract
Background: Peritoneal metastasis (PM) is an ongoing challenge in surgical oncology. Current therapeutic options, including intravenous and intraperitoneal (i.p.) chemotherapies display limited clinical efficacy, resulting in an overall poor prognosis in affected patients. Combined hyperthermia and dehydration induced by a high-flow, gas-based i.p. hyperthermic procedure could be a novel approach in PM treatment. Our study is the first to evaluate the therapeutic potential of i.p. dehydration, hyperthermia, as well as the combination of both mechanisms in an in-vivo setting.
Methods: For this study, three swine were subjected to diagnostic laparoscopy under a high-flow air stream at 48°, 49° and 50°Celsius (C). Hygrometry of the in- and outflow airstream was measured to calculate surface evaporation and i.p. dehydration. To analyze the effects of this concept, in vitro colon cancer cells (HT-29) were treated with hyperthermia and dehydration. Cytotoxicity and cell viability were measured at different time intervals. Additionally, structural changes of dehydrated cells were analyzed using scanning electron microscopy.
Results: According to our results, both dehydration and hyperthermia were cytotoxic to HT-29 cells. However, while dehydration reduced cell viability, hyperthermia did not. However, dehydration effects on cell viability were significantly increased when combined with hyperthermia (p<0.01).
Conclusions: Changes to the physiological milieu of the peritoneal cavity could significantly reduce PM. Therefore, limited dehydration of the abdominal cavity might be a feasible, additional tool in PM treatment. Further studies are required to investigate dehydration effects and their applicability in PM management.
Keywords: colorectal cancer; dehydration; electron microscopy; hyperthermia; peritoneal metastasis (PM).
Copyright © 2022 Diakun, Khosrawipour, Mikolajczyk-Martinez, Nicpoń, Kiełbowicz, Prządka, Liszka, Kielan, Zielinski, Migdal, Lau, Li and Khosrawipour.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
In-vivo thermodynamic exploration of gas-based intraperitoneal hyperthermia.Front Oncol. 2022 Aug 29;12:925724. doi: 10.3389/fonc.2022.925724. eCollection 2022. Front Oncol. 2022. PMID: 36106116 Free PMC article.
-
Safety, feasibility, and application of intraperitoneal gas-based hyperthermia beyond 43°C in the treatment of peritoneal metastasis: An in-vivo pilot study.Front Oncol. 2022 Oct 11;12:953920. doi: 10.3389/fonc.2022.953920. eCollection 2022. Front Oncol. 2022. PMID: 36303827 Free PMC article.
-
Triple-Therapy of Peritoneal Metastasis-Partial-Dehydration under Hyperthermic Condition Combined with Chemotherapy: The First Preliminary In-Vitro Results.Pharmaceuticals (Basel). 2023 May 18;16(5):763. doi: 10.3390/ph16050763. Pharmaceuticals (Basel). 2023. PMID: 37242546 Free PMC article.
-
Does the primary tumour location affect the prognosis of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?World J Surg Oncol. 2021 Aug 26;19(1):253. doi: 10.1186/s12957-021-02374-4. World J Surg Oncol. 2021. PMID: 34446046 Free PMC article.
-
Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis.Surg Clin North Am. 2017 Jun;97(3):671-682. doi: 10.1016/j.suc.2017.01.013. Surg Clin North Am. 2017. PMID: 28501254 Review.
Cited by
-
Enhanced Chemo-Immunotherapy Strategy Utilizing Injectable Thermosensitive Hydrogel for The Treatment of Diffuse Peritoneal Metastasis in Advanced Colorectal Cancer.Adv Sci (Weinh). 2023 Dec;10(35):e2303819. doi: 10.1002/advs.202303819. Epub 2023 Oct 24. Adv Sci (Weinh). 2023. PMID: 37875399 Free PMC article.
-
Research progress and treatment status of malignant ascites.Front Oncol. 2024 Dec 16;14:1390426. doi: 10.3389/fonc.2024.1390426. eCollection 2024. Front Oncol. 2024. PMID: 39737405 Free PMC article. Review.
-
Drug Distribution and Penetration of Foam-Based Intraperitoneal Chemotherapy (FBIC).Pharmaceuticals (Basel). 2023 Oct 2;16(10):1393. doi: 10.3390/ph16101393. Pharmaceuticals (Basel). 2023. PMID: 37895864 Free PMC article.
-
In-vivo thermodynamic exploration of gas-based intraperitoneal hyperthermia.Front Oncol. 2022 Aug 29;12:925724. doi: 10.3389/fonc.2022.925724. eCollection 2022. Front Oncol. 2022. PMID: 36106116 Free PMC article.
-
Intraoperative parameters and postoperative follow-up of foam-based intraperitoneal chemotherapy (FBIC).Front Pharmacol. 2023 Nov 14;14:1276759. doi: 10.3389/fphar.2023.1276759. eCollection 2023. Front Pharmacol. 2023. PMID: 38035016 Free PMC article.
References
-
- Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, et al. . Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol (2019) 37(16):1380–90. doi: 10.1200/JCO.18.01568 - DOI - PMC - PubMed
-
- Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. . Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer. J Clin Oncol (2003) 21(20):3737–43. doi: 10.1200/JCO.2003.04.187 - DOI - PubMed
-
- Oseledchyk A, Zivanovic O. Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. Oncol (Williston Park) (2015) 29(9):695–701. - PubMed
LinkOut - more resources
Full Text Sources